Mondre

Mendra is an AI-native biotechnology company focused on developing precision medicines for rare diseases with high unmet medical needs. Launched in early 2026 with an $82 million Series A financing round, the company leverages advanced computational tools and artificial intelligence to accelerate drug discovery and clinical development. Mendra's leadership team includes seasoned industry veterans from BioMarin and Palantir, bringing deep expertise in rare disease strategy and large-scale data integration. The company's initial research efforts target novel mechanisms of action, including G protein-coupled receptors (GPCRs) implicated in endocrine and cardiovascular disorders. By integrating translational, clinical, and computational insights, Mendra aims to redefine the standard of care for patients suffering from rare and complex conditions.